Actuate Therapeutics (ACTU) Preferred Stock Liabilities (2023 - 2024)
Actuate Therapeutics (ACTU) posted quarterly Preferred Stock Liabilities of $94.2 million for Q2 2024, little changed quarter-over-quarter from $94.2 million in Q4 2023.
Actuate Therapeutics (ACTU) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Preferred Stock Liabilities for 2 consecutive years, with $94.2 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Preferred Stock Liabilities changed N/A year-over-year to $94.2 million; the TTM figure through Jun 2024 stood at $94.2 million (changed N/A YoY), while the FY2023 annual figure was $94.2 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $94.2 million in Q2 2024 per ACTU's latest filing, from $94.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $94.2 million in Q4 2023 and bottomed at $94.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 94.18 Mn |
| Dec 31, 2023 | 94.18 Mn |